meglumine has been researched along with Nephrogenic Systemic Fibrosis in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (14.29) | 29.6817 |
| 2010's | 22 (78.57) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Davenport, MS; Gagnier, JJ; MacEachern, MP; Shankar, PR; Singer, L; Woolen, SA | 1 |
| Kalantari, K; Swaminathan, S | 1 |
| Kalb, B; Martin, DR; Mittal, A; Mittal, PK; Salman, K; Vedantham, S | 1 |
| Houston, JG; Matthew, SZ; Young, LK | 1 |
| Flynn, MM; Lipowska, AM; Parekh, AN; Parikh, MR; Perez, SD; Runge, TM; Sakaria, SS; Shaffer, KM; Sood, A; Subramanian, RM | 1 |
| Chang, DH; Pracros, JP | 1 |
| Abu Alfa, AK; Bauer, K; Belknap, SM; Bhatt, K; Bull, C; Cowper, SE; Edwards, BJ; Fisher, MJ; Hammel, JA; Kanal, E; Laumann, AE; McKoy, JM; Miller, FH; Nardone, B; Raisch, DW; Restaino, J; Saddleton, E; Samaras, AT; Thomsen, HS; West, DP | 1 |
| Kirchin, MA; Lorusso, V; Pirovano, G | 1 |
| Cox, KL; Moreno, CC; Nandwana, SB; Osipow, MT; Sekhar, A | 1 |
| Abujudeh, HH; Bloomgarden, DC; Kirchin, MA; Kuhn, MJ; Lichtenstein, RJ; Liou, J; Maki, JH; Mennitt, KW; Morgan, DE; Pirovano, G; Rofsky, NM; Russo, C; Schiebler, ML; Semelka, RC; Shen, N; Smith, MP; Soulez, G; Spinazzi, A; Stolpen, A; Wippold, FJ | 1 |
| Brooks, WM; Laurence, JS; Lee, P; McCarthy, ET; Rowe, PS; Zelenchuk, LV | 1 |
| Kay, J; Todd, DJ | 1 |
| Bruce, R; Djamali, A; Garrett, RW; Haemel, AK; Sadowski, DR; Sadowski, EA; Wentland, AL | 1 |
| de Kerviler, E; Desché, P; Dubourdieu, C; Jullien, V; Maravilla, K; Meder, JF; Naggara, O | 1 |
| Dohan, A; Gottschalk, A; Patkar, D; Soyer, P | 1 |
| Goyen, M; Herborn, CU; Jäger-Booth, I; Lodemann, KP; Spinazzi, A | 1 |
| Broome, DR; Bryant, BJ; Im, K | 1 |
| Altun, E; Fuller, ER; Lugo-Somolinos, A; Martin, DR; Semelka, RC; Wertman, R | 1 |
| Abujudeh, HH; Agarwal, S; Gebreananya, ZA; Kaewlai, R; Kay, J; Rolls, H; Saini, S; Schaefer, PW | 1 |
| Chrysochou, C; Husain, S; Kalra, PA; Lay, J; Moser, S; Power, A; Salama, AD; Shurrab, AE | 1 |
| Burden, AD; Edward, M; Jardine, AG; Newton, BB; Quinn, JA | 1 |
| Perazella, MA; Reilly, RF | 1 |
| Brill, PW; Prince, MR; Staron, RB; Zhang, H; Zou, Z | 1 |
| de Campos, RO; De Toni, MS; Fuller, ER; Heredia, V; Lugo-Somolinos, A; Ramalho, M; Semelka, RC | 1 |
| Carr, JC; Carroll, TJ; Collins, JD; Davarpanah, AH; Kalisz, KR; Usman, AA | 1 |
| Bains, S; Factor, C; Fretellier, N; Idée, JM; Jestin, G; Johnson, C; MacNeil, S; Morcos, SK | 1 |
| Haylor, J; Idée, JM; Jestin, G; Morcos, S; Nutter, F; Schroeder, J; Wagner, B | 1 |
| Grosse-Wortmann, L; Meng, H | 1 |
2 review(s) available for meglumine and Nephrogenic Systemic Fibrosis
| Article | Year |
|---|---|
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Topics: Contraindications, Drug; Contrast Media; Gadolinium; Glomerular Filtration Rate; Heterocyclic Compounds; Humans; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk; Severity of Illness Index; United States; United States Food and Drug Administration | 2020 |
Gadolinium-Induced Fibrosis.
Topics: Animals; Contrast Media; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Terminology as Topic | 2016 |
3 trial(s) available for meglumine and Nephrogenic Systemic Fibrosis
| Article | Year |
|---|---|
Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?
Topics: Animals; Bile; Chromatography, High Pressure Liquid; Contrast Media; Disease Models, Animal; Ions; Kidney; Liver; Male; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Rats; Urine | 2015 |
Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Contrast Media; Female; Humans; Incidence; Infant; Infant, Newborn; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Observational Studies as Topic; Organometallic Compounds; Product Surveillance, Postmarketing; Risk Assessment; Young Adult | 2016 |
[Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
Topics: Adolescent; Adult; Aged; Brain; Child; Child, Preschool; Contrast Media; Dose-Response Relationship, Drug; Female; Germany; Humans; Image Enhancement; Image Processing, Computer-Assisted; Infant; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Risk Factors; Spinal Cord; Young Adult | 2009 |
23 other study(ies) available for meglumine and Nephrogenic Systemic Fibrosis
| Article | Year |
|---|---|
Use of Gadolinium in Individuals with Reduced Kidney Function.
Topics: Aged; Contrast Media; Gadolinium; Glomerular Filtration Rate; Humans; Magnetic Resonance Imaging; Male; Meglumine; Nephrectomy; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Pancreatic Neoplasms; Renal Dialysis; Risk Assessment | 2021 |
Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease.
Topics: Adolescent; Adult; Aged; Contrast Media; Female; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Young Adult | 2018 |
Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Contrast Media; Drug Hypersensitivity; Female; Gadolinium; Glomerular Filtration Rate; Humans; Incidence; Infant; Infant, Newborn; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Physical Examination; Retrospective Studies; Risk Factors; Young Adult | 2019 |
Renal Safety of Intravenous Gadolinium-enhanced MRI in Patients Following Liver Transplantation.
Topics: Acute Kidney Injury; Administration, Intravenous; Adult; Aged; Biomarkers; Contrast Media; Creatinine; Female; Georgia; Humans; Incidence; Liver Transplantation; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Postoperative Complications; Renal Insufficiency; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2019 |
Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study.
Topics: Adolescent; Child; Child, Preschool; Contrast Media; Female; Humans; Image Enhancement; Infant; Magnetic Resonance Imaging; Male; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Prospective Studies | 2019 |
Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.
Topics: Contrast Media; Cooperative Behavior; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Male; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Pharmacovigilance; Registries; United States | 2014 |
Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Topics: Adolescent; Adult; Aged; Contrast Media; Female; Humans; Incidence; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Renal Insufficiency; Retrospective Studies; Risk Assessment; Young Adult | 2015 |
Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Topics: Adolescent; Adult; Aged; Contrast Media; Female; Gadolinium; Heterocyclic Compounds; Humans; Kidney Failure, Chronic; Kidney Function Tests; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Product Surveillance, Postmarketing; Prospective Studies; Risk Factors | 2015 |
Do ASARM peptides play a role in nephrogenic systemic fibrosis?
Topics: Animals; Contrast Media; Cytoprotection; Disease Models, Animal; Drug Stability; Extracellular Matrix Proteins; Familial Hypophosphatemic Rickets; Fibroblast Growth Factor-23; Gadolinium DTPA; Glycoproteins; Kidney; Magnetic Resonance Imaging; Male; Meglumine; Mice, Inbred C57BL; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Peptide Fragments; PHEX Phosphate Regulating Neutral Endopeptidase; Phosphoproteins; Protein Binding; Protein Interaction Domains and Motifs; Signal Transduction; X-Ray Microtomography | 2015 |
Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
Topics: Comorbidity; Contrast Media; Gadolinium DTPA; Glomerular Filtration Rate; Humans; Image Enhancement; Incidence; Magnetic Resonance Imaging; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Renal Insufficiency; Retrospective Studies; Risk Assessment; Risk Factors | 2016 |
Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asia; Child; Child, Preschool; Contrast Media; Europe; Female; Follow-Up Studies; Humans; Image Enhancement; Incidence; Infant; Internationality; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Prospective Studies; Risk Factors; Young Adult | 2017 |
Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
Topics: Adult; Aged; Aged, 80 and over; California; Contrast Media; Dose-Response Relationship, Drug; Female; Humans; Incidence; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Prospective Studies; Renal Insufficiency | 2009 |
Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Topics: Contrast Media; Female; Gadolinium DTPA; Humans; Incidence; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Renal Dialysis; Retrospective Studies; Risk Factors; United States | 2009 |
Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Contrast Media; Female; Humans; Magnetic Resonance Imaging; Male; Massachusetts; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Practice Guidelines as Topic; Prevalence; Renal Insufficiency; Retrospective Studies; Risk Assessment; Risk Factors | 2009 |
Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
Topics: Adult; Aged; Chronic Disease; Contrast Media; England; Female; Gadolinium; Gadolinium DTPA; Glomerular Filtration Rate; Humans; Kidney Diseases; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Patient Selection; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors | 2010 |
Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
Topics: Adult; Cell Proliferation; Collagen; Contrast Media; Dose-Response Relationship, Drug; Edetic Acid; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Hyaluronic Acid; Linear Models; Magnetic Resonance Imaging; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds | 2010 |
Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Topics: Acute Kidney Injury; Contrast Media; Diagnostic Imaging; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Informed Consent; Iodine Radioisotopes; Magnetic Resonance Imaging; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Patient Selection; Radiopharmaceuticals; Renal Artery Obstruction; Risk Assessment; Risk Factors; Tomography, X-Ray Computed | 2011 |
Incidence of immediate gadolinium contrast media reactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaphylaxis; Cause of Death; Child; Child, Preschool; Contrast Media; Drug Hypersensitivity; Female; Gadolinium; Gadolinium DTPA; Humans; Incidence; Infant; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Retrospective Studies; United States; Young Adult | 2011 |
Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Feasibility Studies; Female; Humans; Kidney Diseases; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Pregnancy; Retrospective Studies; Risk Factors; Statistics, Nonparametric | 2011 |
Detection of renal dysfunction by point-of-care creatinine testing in patients undergoing peripheral MR angiography.
Topics: Aged; Analysis of Variance; Comorbidity; Contrast Media; Creatinine; Female; Gadolinium DTPA; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Magnetic Resonance Angiography; Male; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Point-of-Care Systems; Prevalence; Retrospective Studies; Risk Factors; Surveys and Questionnaires | 2011 |
Gadolinium contrast agent associated stimulation of human fibroblast collagen production.
Topics: Chromatography, High Pressure Liquid; Collagen; Colorimetry; Contrast Media; Edetic Acid; Fibroblasts; Gadolinium DTPA; Humans; Keratinocytes; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Skin | 2011 |
Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis.
Topics: Animals; Contrast Media; Disease Models, Animal; Gadolinium DTPA; Immunoenzyme Techniques; Male; Meglumine; Microscopy, Electron, Transmission; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Rats; Rats, Wistar; Skin; Spectrophotometry, Atomic | 2012 |
Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice.
Topics: Adolescent; Age Factors; Benchmarking; Child; Child, Preschool; Contrast Media; Gadolinium; Gadolinium DTPA; Glomerular Filtration Rate; Health Care Surveys; Humans; Infant; Infant, Newborn; Kidney; Magnetic Resonance Imaging; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Practice Guidelines as Topic; Practice Patterns, Physicians'; Risk Assessment; Risk Factors; Surveys and Questionnaires | 2012 |